Posted on 2/1/21
Johnson & Johnson Says Its One-Dose Coronavirus Vaccine Was 66% Effective in Clinical Trial
Johnson & Johnson (NYSE:JNJ) released results today from the phase 3 clinical trial of its COVID-19 vaccine candidate, saying that the data showed it was 66% . . .
Posted on 1/26/21
Merck Gives Up on Coronavirus Vaccines
Pharmaceutical giant Merck (NYSE:MRK) officially threw in the towel on its efforts to develop a COVID-19 vaccine. The company said it's discontinuing the development of two . . .
Posted on 1/26/21
Moderna Says Vaccine Protects Against All Known Variants
Moderna (NASDAQ:MRNA) announced evidence that its COVID-19 vaccine is protective against all variants of the SARS-CoV-2 virus detected to date, including two strains first detected in . . .
Posted on 1/21/21
Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant
Vaccine partners Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) released information today that provides new evidence that their COVID-19 vaccine is effective against the B.1.1.7 variant that was . . .
Posted on 12/10/20
DexCom Has a Lot to Prove in 2021
As the adage goes, two things in life are inevitable: death and taxes. Experienced growth investors might want to add a third inescapable truth to that . . .
Posted on 12/1/20
Should You Sell Teladoc Health Stock As Coronavirus Vaccines Succeed?
As the world stands on the verge of getting vaccines for COVID-19, investors interested in the pandemic theme are faced with a dilemma. Do they sell . . .
Posted on 11/4/20
Bristol Myers Squibb Reports Success in Pivotal Trial of Psoriasis Drug
Bristol Myers Squibb (NYSE:BMY) on Tuesday announced positive results from a phase 3 trial of deucravacitinib in patients with moderate to severe plaque psoriasis. The drug, . . .
Posted on 10/26/20
How Much Is Moderna Really Worth?
The world's desperate need for vaccines and treatments to fight the COVID-19 pandemic has thrust a few companies into the limelight, including Moderna. The Massachusetts-based biotech, . . .
Posted on 10/7/20
Why Is Everyone Talking About Novavax Stock?
Any stock that skyrockets over 4,600% from the beginning of a year through early August is bound to create a lot of buzz in the investment . . .
Posted on 9/22/20
Illumina to Acquire Cancer Diagnostics Start-up Grail
Gene-sequencing giant Illumina (NASDAQ:ILMN) confirmed last week's rumor that it's buying Grail, a start-up working on early detection of cancer using DNA analysis of blood samples,
Posted on 9/3/20
Why These 3 Coronavirus Stocks Are Falling This Week
Shares of COVID-19 vaccine developers Moderna (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX), and Pfizer (NYSE:PFE) have fallen this week after presentations to the Centers for Disease Control (CDC) revealed . . .
Posted on 8/21/20
How Has DexCom Stock Performed in 2020 So Far?
Few things will both propel a stock and obliterate expectations during a time when the rest of the industry is struggling. DexCom (NASDAQ:DXCM), maker of continuous . . .
Posted on 8/18/20
Novavax Launches Midstage Coronavirus Vaccine Trial
Vaccine specialist Novavax (NASDAQ:NVAX) announced the launch of a phase 2b clinical trial in South Africa to test the effectiveness of its coronavirus vaccine, NVX-CoV2373. The . . .
Posted on 7/29/20
3 Reasons to Buy Moderna Stock, and 1 Reason to Sell It
The share price of clinical-stage biotech Moderna (NASDAQ:MRNA) has risen 245% since it announced on Feb. 10 that it had already designed and produced its first . . .
Posted on 7/23/20
Better Buy: Teladoc vs. Livongo Health
The COVID-19 pandemic has provided a major boost to companies in the emerging field of remote healthcare. The use of technology to extend healthcare beyond the . . .
Posted on 7/14/20
Pfizer and BioNTech Get "Fast Track" Designation for 2 COVID-19 Vaccines
German biotech BioNTech SE (NASDAQ:BNTX) and its partner Pfizer (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to two . . .
Posted on 6/15/20
bluebird bio Reports Dramatic Improvement in Sickle Cell Patients with LentiGlobin Gene Therapy
Gene therapy company bluebird bio (NASDAQ:BLUE) gave an update on the clinical trial of its treatment for sickle cell disease (SCD) showing that patients in the . . .
Posted on 6/1/20
2 Warren Buffett Stocks to Buy in June
Despite an investor stampede for the exits in the month of March that put a lot of stocks on sale, Warren Buffett's Berkshire Hathaway did surprisingly . . .
Posted on 4/30/20
Catalent and Johnson & Johnson Sign Coronavirus Vaccine Manufacturing Deal
Shares of drug manufacturer Catalent (NYSE:CTLT) were up by 10% at 2 p.m. Wednesday after the company announced it had signed an agreement with the Janssen . . .
Posted on 4/30/20
Boston Scientific Stock Rises on Sales Increase, Positive Management Outlook
A slowdown in medical procedures due to the COVID-19 pandemic caused a decline in first-quarter profits at medical device maker Boston Scientific (NYSE:BSX), but the company . . .
Posted on 4/28/20
FDA Approves Neurocrine Biosciences' Parkinson's Drug
Neurocrine Biosciences (NASDAQ:NBIX) announced Monday that the Food and Drug Administration (FDA) has approved Ongentys (opicapone), a daily pill for Parkinson's disease.Ongentys is an add-on treatment . . .
Posted on 4/22/20
Cara Therapeutics Reports Success for Korsuva in Pivotal Trial
Shares of clinical-stage biotech Cara Therapeutics (NASDAQ:CARA) rose 4% Tuesday after the company reported successful results from a phase 3 trial of its lead drug Korsuva . . .
Posted on 4/20/20
Is ResMed Stock a Buy?
The COVID-19 pandemic has focused attention on a potential shortage of ventilators to keep the most severely affected patients alive when their lungs are overwhelmed by . . .
Posted on 3/24/20
Is Emergent BioSolutions Stock a Buy?
The public crisis that is the COVID-19 pandemic has some companies scrambling to survive, and others working hard to contribute to solving the problem. Investors, meanwhile, . . .
Posted on 2/28/20
Teladoc Health Soars After Reporting Strong Q4 Results
Virtual healthcare provider Teladoc Health (NYSE:TDOC) reported fourth-quarter earnings that beat expectations and gave strong guidance for the year ahead, propelling the stock up 15% in . . .
Posted on 2/28/20
Sage Therapeutics Disappoints With Its Q4 Report
Shares of Sage Therapeutics (NASDAQ:SAGE) tumbled Thursday morning after the company reported slower-than-expected revenue growth for its drug for post-partum depression (PPD), and didn't have anything . . .
Posted on 2/27/20
Teladoc Health Soars After Reporting Strong Q4 Results
Virtual healthcare provider Teladoc Health (NYSE:TDOC) reported fourth-quarter earnings that beat expectations and gave strong guidance for the year ahead, propelling the stock up 15% in . . .
Posted on 2/24/20
Emergent BioSolutions Reports Mixed Results for Q4
Emergent BioSolutions (NYSE:EBS) reported fourth-quarter earnings that beat top-line expectations but missed on profit estimates. The company, which focuses on drugs, vaccines, and medical devices that . . .
Posted on 2/7/20
Regeneron Shares Rise on Earnings, Coronavirus Work
Regeneron Pharmaceuticals (NASDAQ:REGN) reported fourth-quarter results that beat expectations, and investors -- who have been snapping up the stock this week based on news that it's . . .
Posted on 2/6/20
Merck Announces a Big Planned Spinoff
Merck (NYSE:MRK) announced Wednesday its intention to spin off its women's health business, legacy brands, and biosimilars unit into an independent, publicly traded company, and reorient . . .
Posted on 2/4/20
Merck's Insomnia Drug Approved for Alzheimer's Patients
Merck (NYSE:MRK) received approval from the U.S. Food and Drug Administration to market its insomnia drug Belsomra (suvorexant) for treating sleep disruption in patients with mild-to-moderate . . .
Posted on 1/29/20
Pfizer's Q4 Results, 2020 Guidance Leave Investors Cold
Pharmaceutical giant Pfizer (NYSE:PFE) reported fourth-quarter results Tuesday that beat expectations for revenue, but missed on the bottom line. That miss, combined with weak profit guidance, . . .
Posted on 1/16/20
Novavax Wins Fast-Track Designation for Flu Vaccine
Shares of Novavax (NASDAQ:NVAX) were up more than 10% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted its next-generation flu . . .
Posted on 1/16/20
Novavax Wins Fast-Track Designation for Flu Vaccine
Shares of Novavax (NASDAQ:NVAX) were up more than 10% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted its next-generation flu . . .
Posted on 1/14/20
Biogen Buys Azheimer's and Parkinson's Drug From Pfizer
Biogen (NASDAQ:BIIB) announced it has reached an agreement with Pfizer (NYSE:PFE) to buy a drug in early development that is designed to treat debilitating symptoms related . . .
Posted on 12/18/19
7 Reasons Teladoc Will Be a Top Growth Stock in 2020
With interest rates and inflation near record lows, recession concerns subsiding, and the upcoming election providing an incentive for the Trump administration to tamp down worries . . .
Posted on 10/9/19
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
Investing in biotechnology stocks can sometimes feel more like gambling than serious wealth-building. Company success usually rides on the binary events of clinical trials and regulatory . . .
Posted on 7/8/19
Is bluebird bio a Buy?
Gene therapy stocks attracted frenzied attention from investors in 2017 and early 2018, and with good reason. New technologies to manipulate the very software of life . . .
Posted on 7/8/19
Is bluebird bio a Buy?
Gene therapy stocks attracted frenzied attention from investors in 2017 and early 2018, and with good reason. New technologies to manipulate the very software of life . . .
Posted on 5/20/19
Where Will Pfizer Be in 5 Years?
Drug stocks have taken a hit lately as the market has started to worry about political pressures that may come to bear on pricing and affect . . .
Posted on 5/20/19
Where Will Pfizer Be in 5 Years?
Drug stocks have taken a hit lately as the market has started to worry about political pressures that may come to bear on pricing and affect . . .
Posted on 4/23/19
Better Buy: Biogen vs. AbbVie
Healthcare stocks have been hammered recently after the market seemed to suddenly wake up to the possibility that politicians may make some policy changes that cut . . .
Posted on 3/5/19
Stock Market Today: Biogen Buys Gene Therapy Company Nightstar Therapeutics
It was an up-and-down session on Wall Street Monday, with stocks opening higher but falling in the morning. The Dow Jones Industrial Average (DJINDICES:^DJI) and the . . .
Posted on 2/21/19
Better Buy: Pfizer vs. Eli Lilly
Large pharmaceutical companies generate healthy cash flows, part of which they usually return to shareholders in the form of dividends and share buybacks. But these businesses . . .
Posted on 2/21/19
Better Buy: Pfizer vs. Eli Lilly
Large pharmaceutical companies generate healthy cash flows, part of which they usually return to shareholders in the form of dividends and share buybacks. But these businesses . . .
Posted on 11/29/18
Better Buy: Rite Aid vs. Walgreens Boots Alliance
It seems there's a neighborhood pharmacy on every street corner of the neighborhood. An investor could get dizzied when deciding which modernized convenience store chain, if . . .
Posted on 8/16/18
Akcea Therapeutics Soars as It Readies Its First Drug Launch
One year after Akcea Therapeutics (NASDAQ:AKCA) was spun off from Ionis Pharmaceuticals (NASDAQ:IONS) in order to commercialize drugs to treat rare metabolic diseases, Akcea is poised . . .
Posted on 7/18/18
The Picture for Cara Therapeutics Just Got Clearer
Shareholders of small-cap biotech Cara Therapeutics (NASDAQ:CARA) have had a bumpy ride the last couple of years. Hopes were flying high in early 2017, only to . . .
Posted on 5/18/18
Forget Cara Therapeutics' Earnings -- Here's the Real News
Ordinarily, a report of zero revenue in a quarter would not be too well received by investors. That was exactly the top-line result for Cara Therapeutics . . .
Posted on 12/19/17
Is Cara Therapeutics, Inc. a Buy?
Small-cap biotech Cara Therapeutics (NASDAQ:CARA) is working to commercialize a drug to combat pain -- but the stock has managed to inflict a different sort of . . .
Philadelphia
